- Winning scientific poster shows complete tumor regression and high tolerability of SYNtecan E™ based ADCs
- SYNtecan E™ linker-payload is developed by Synaffix based on the potent DNA topoisomerase 1 inhibiting exatecan
- Additionally, Synaffix was awarded ‘Runner-Up’ for the 2021 Best ADC Platform Technology (Winner in 2020)
AMSTERDAM, NETHERLANDS – 28 October 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index today announces that the Company was awarded Best Poster at Hanson Wade’s 2021 World ADC Conference. Separately, Synaffix was also awarded ‘Runner-Up’ for the Best ADC Platform Technology.